A Scottish Biotech Just Raised $46M to Tackle a Rare Kidney Disease

·
Listen to this article~4 min

Glasgow-based Mironid has raised $46 million in Series B funding to advance its lead drug candidate for ADPKD, a rare kidney disease affecting millions worldwide. The round was led by the Scottish National Investment Bank, with support from Roche Venture Fund and others.

When a biotech company lands a big funding round, it's easy to get lost in the dollar signs. But behind the numbers, there's often a story about real people waiting for better treatments. That's exactly what's happening with Mironid, a Glasgow-based biopharmaceutical company that just closed a $46 million Series B round to push its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through clinical development. ### The Funding Round at a Glance The round was led by the Scottish National Investment Bank, with participation from existing backers like Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. That's a pretty impressive lineup, and it says a lot about the confidence in Mironid's approach. Neil Wilkie, Mironid's CEO, didn't mince words about the significance of the support: "ADPKD is the most common hereditary kidney disorder, affecting over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60. Securing funding from such a high-calibre syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD." ### What Is ADPKD, and Why Does It Matter? ADPKD is a genetic condition where fluid-filled cysts grow uncontrollably in the kidneys. Over time, these cysts can crowd out healthy tissue, leading to kidney failure. It's caused by mutations in the PKD1 or PKD2 genes, and it's the fourth leading cause of kidney failure worldwide. For many patients, the only long-term option is dialysis or a transplant—so new treatments that could slow or stop the disease would be a game-changer. ### Mironid's Unique Approach Mironid's lead candidate is a first-in-class "LoAc" small molecule that targets cyclic AMP (cAMP), a cellular signal that drives both cyst growth and fluid secretion. The company believes that by modulating cAMP, they can prevent new cysts from forming and stop existing ones from growing. Preclinical data has shown significant efficacy and a favorable safety profile, including reductions in cyst number and kidney volume. If that holds up in human trials, it could offer a more durable treatment option with fewer side effects than current therapies. ### More Than Just One Drug Beyond ADPKD, Mironid's pipeline also targets phosphodiesterase 4 (PDE4) enzymes, which are involved in inflammatory diseases and cancer. The company was spun out of the University of Strathclyde and Heriot-Watt University in 2015, building on over three decades of research into PDE biology. It's a classic example of how university research can translate into real-world impact. ### What's Next? The fresh capital will go toward advancing the clinical development of Mironid's lead candidate. According to Paul Callaghan, Investment Director at the Scottish National Investment Bank, "Mironid exemplifies Scotland's growing reputation for biotech innovation... We are pleased to join a committed group of investors to support the company through this critical stage of development." This Series B follows an earlier Series A extension that brought Mironid's total funding to roughly $48 million since inception. With this new backing, the company is well-positioned to move its promising therapy into the next phase of trials—and potentially bring hope to millions of people living with ADPKD. For anyone watching the biotech space, this is one to keep an eye on.

📌 Worth Reading Next